Huateng Pharmaceutical, a global supplier of pharmaceutical intermediates, offers SELEXIPAG / NS-304 / ACT-293987 (CAS No.: 475086-01-2) for your requirements of R&D, evaluation, pilots and commercial along with supportive technical package required for evaluation.

Selexipag is an orally available, highly selective, long-acting prostacyclin (IP) receptor agonist prodrug. It is a potential drug for the treatment of various vascular disorders such as pulmonary arterial hypertension and arteriosclerosis obliterans.

Find More Selexipag/UPTRAVI Intermediates>>>